Primary Prevention of Thrombosis in Subjects with Positive Antiphospholipid Antibodies
- 1 September 2000
- journal article
- review article
- Published by Elsevier in Journal of Autoimmunity
- Vol. 15 (2) , 249-253
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trialThe Lancet, 2000
- Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patientsLupus, 1998
- Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased riskThe Lancet, 1998
- Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus—A meta-analysisLupus, 1997
- Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the italian registryThe American Journal of Medicine, 1996
- Anti-Cardiolipin Antibodies and Risk of Myocardial Infarction in a Prospective Cohort of Middle-Aged MenCirculation, 1995
- Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patientsBMJ, 1994
- Anticardiolipin Antibodies and the Risk for Ischemic Stroke and Venous ThrombosisAnnals of Internal Medicine, 1992
- Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosusSeminars in Arthritis and Rheumatism, 1992
- Antiphospholipid Antibodies: Anticardiolipin and the Lupus Anticoagulant in Systemic Lupus Erythematosus (SLE) and in Non-SLE DisordersAnnals of Internal Medicine, 1990